Sarepta Therapeutics, Inc.SRPTNASDAQ
LOADING
|||
EPS Growth Under Pressure
Trending lower, below historical average, modest growth trend.
Left:
||||
Year-over-year earnings per share growth rate
Latest
-189.31%
↓ 572% below average
Average (39q)
-28.18%
Historical baseline
Range
High:400.00%
Low:-739.13%
CAGR
+6.7%
Consistent expansion
| Period | Value |
|---|---|
| Q3 2025 | -189.31% |
| Q2 2025 | 143.70% |
| Q1 2025 | -378.79% |
| Q4 2024 | 371.43% |
| Q3 2024 | 400.00% |
| Q2 2024 | -81.58% |
| Q1 2024 | -22.45% |
| Q4 2023 | 206.52% |
| Q3 2023 | -70.37% |
| Q2 2023 | 95.39% |
| Q1 2023 | -372.58% |
| Q4 2022 | 57.82% |
| Q3 2022 | -10.94% |
| Q2 2022 | -120.83% |
| Q1 2022 | 17.24% |
| Q4 2021 | -141.67% |
| Q3 2021 | 41.18% |
| Q2 2021 | 51.43% |
| Q1 2021 | 12.86% |
| Q4 2020 | 3.60% |
| Q3 2020 | -29.53% |
| Q2 2020 | -739.13% |
| Q1 2020 | 92.79% |
| Q4 2019 | -87.65% |
| Q3 2019 | 54.55% |
| Q2 2019 | -249.53% |
| Q1 2019 | 47.80% |
| Q4 2018 | -78.26% |
| Q3 2018 | 31.14% |
| Q2 2018 | -203.64% |
| Q1 2018 | -48.65% |
| Q4 2017 | 52.56% |
| Q3 2017 | 32.17% |
| Q2 2017 | -175.16% |
| Q1 2017 | 194.44% |
| Q4 2016 | -37.29% |
| Q3 2016 | 12.59% |
| Q2 2016 | -3.05% |
| Q1 2016 | 9.03% |
| Q4 2015 | -15.20% |